WAVE Life Sciences Ltd. saw a significant price drop of 15.20%, crossing below its 5-day SMA, amid broader market weakness with the Nasdaq-100 down 1.26% and the S&P 500 down 0.40%.
This decline is attributed to the company's announcement of a $350 million public offering of shares and warrants, which is expected to enhance its financial strength for RNA drug development. The offering includes pre-funded warrants and is managed by Jefferies, Leerink Partners, and BofA Securities, indicating strong market confidence despite the current market conditions.
The implications of this offering are significant as it aims to support Wave's ongoing clinical projects and enhance its competitiveness in the RNA therapeutics sector, although the market's reaction reflects caution amid the overall downturn.
Wall Street analysts forecast WVE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WVE is 33.00 USD with a low forecast of 21.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
Wall Street analysts forecast WVE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WVE is 33.00 USD with a low forecast of 21.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Buy
0 Hold
0 Sell
Strong Buy
Current: 12.730
Low
21.00
Averages
33.00
High
50.00
Current: 12.730
Low
21.00
Averages
33.00
High
50.00
H.C. Wainwright
Andrew Fein
Buy
upgrade
$22 -> $30
2025-12-19
Reason
H.C. Wainwright
Andrew Fein
Price Target
$22 -> $30
AI Analysis
2025-12-19
upgrade
Buy
Reason
H.C. Wainwright analyst Andrew Fein raised the firm's price target on Wave Life Sciences to $30 from $22 and keeps a Buy rating on the shares. The firm says its key opinion leader validation and dose-response modeling confirm WVE-007 as a potential "body recomposition" agent, delivering 9.4% visceral fat loss and 3.2% lean mass gain with zero GI issues. Experts identify a significant unmet need for this profile as both a "maintenance" offramp and a synergistic add-on to GLP-1s, uniquely solving the issues of visceral adiposity, muscle loss, and weight rebound, Wainwright adds. The firm's modeling indicates that higher doses will accelerate fat loss to competitive levels, while the clean safety profile clears the path for a differentiated commercial label. Wainwright views upcoming competitor readouts not as threats, but as class validation, positioning Wave to own the "quality" weight loss vertical.
Oppenheimer
Oppenheimer
Outperform
maintain
$24 -> $32
2025-12-16
Reason
Oppenheimer
Oppenheimer
Price Target
$24 -> $32
2025-12-16
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Wave Life Sciences to $32 from $24 and keeps an Outperform rating on the shares following the interim results for WVE-007 and the follow-through last week. To the firm, the most important takeaways from the highly encouraging update are the clean safety profile and the clear translatability from human genetics and preclinical work to clinical results for WVE-007. Oppenheimer is optimistic that the data will further improve with longer follow-up/higher doses, and in subsequent studies.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for WVE
Unlock Now
Truist
Buy
maintain
$36 -> $50
2025-12-15
Reason
Truist
Price Target
$36 -> $50
2025-12-15
maintain
Buy
Reason
Truist raised the firm's price target on Wave Life Sciences to $50 from $36 and keeps a Buy rating on the shares. The firm's obesity model for WVE-007 is a "conservative placeholder" as it tracks maturing data that may fundamentally shift the conversation from "weight loss" to "quality weight loss" that could drive greater utilization of WVE-007 at higher premium if successfully developed, the analyst tells investors in a research note. Truist expects competition but also views Wave Life Sciences' stereopure siRNA platform with innovative backbone chemistry as has having a strong moat that has now been validated through four consecutive successful data readouts, the firm added.
B. Riley
Buy
upgrade
$19 -> $37
2025-12-12
Reason
B. Riley
Price Target
$19 -> $37
2025-12-12
upgrade
Buy
Reason
B. Riley raised the firm's price target on Wave Life Sciences to $37 from $19 and keeps a Buy rating on the shares reflecting strategic value and projected obesity-related revenues. Despite minimal absolute weight loss at the low dose of WVE-007, preclinical modeling suggests continued efficacy, and upcoming obesity and RNA-editing catalysts are expected to provide tailwinds through 2026, the analyst tells investors in a research note.
About WVE
Wave Life Sciences Ltd. is a biotechnology company focused on unlocking the broad potential of ribonucleic acid (RNA) medicines to transform human health. The Company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company’s diversified pipeline includes clinical programs in alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the Company’s broad RNA therapeutics toolkit. Its programs include WVE-006, SERPINA1 (AATD); WVE-007 (GalNAc), INHBE (Obesity); WVE-N531, Exon 53 (DMD), and WVE-003, mHTT (HD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
